SG11202003453QA - Method of treating acid-base disorders - Google Patents

Method of treating acid-base disorders

Info

Publication number
SG11202003453QA
SG11202003453QA SG11202003453QA SG11202003453QA SG11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA SG 11202003453Q A SG11202003453Q A SG 11202003453QA
Authority
SG
Singapore
Prior art keywords
treating acid
base disorders
disorders
base
treating
Prior art date
Application number
SG11202003453QA
Inventor
Gerrit Klaerner
Jerry M Buysse
Jun Shao
Dawn Parsell Otto
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of SG11202003453QA publication Critical patent/SG11202003453QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202003453QA 2017-11-03 2018-11-03 Method of treating acid-base disorders SG11202003453QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581448P 2017-11-03 2017-11-03
US201862748363P 2018-10-19 2018-10-19
PCT/US2018/059093 WO2019090177A1 (en) 2017-11-03 2018-11-03 Method of treating acid-base disorders

Publications (1)

Publication Number Publication Date
SG11202003453QA true SG11202003453QA (en) 2020-05-28

Family

ID=66333602

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003453QA SG11202003453QA (en) 2017-11-03 2018-11-03 Method of treating acid-base disorders

Country Status (7)

Country Link
US (1) US20210187011A1 (en)
EP (1) EP3703707A4 (en)
AU (1) AU2018360868A1 (en)
CA (1) CA3080143A1 (en)
IL (1) IL274223A (en)
SG (1) SG11202003453QA (en)
WO (1) WO2019090177A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3003327T (en) 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
CA3205149A1 (en) 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP4053179A1 (en) 2021-03-01 2022-09-07 Tricida Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3003327T (en) * 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
CA2929978C (en) * 2013-11-08 2021-11-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
IL262660B2 (en) * 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders

Also Published As

Publication number Publication date
US20210187011A1 (en) 2021-06-24
IL274223A (en) 2020-06-30
WO2019090177A1 (en) 2019-05-09
EP3703707A1 (en) 2020-09-09
AU2018360868A1 (en) 2020-04-30
CA3080143A1 (en) 2019-05-09
EP3703707A4 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods of treating fgf21-associated disorders
ZA202006746B (en) Methods of treatment
IL262660A (en) Compositions for and method of treating acid-base disorders
IL279308A (en) Methods for treating hepcidin-mediated disorders
IL274223A (en) Method of treating acid-base disorders
IL269082A (en) Methods of treating lysosomal disorders
IL273960A (en) Compositions for and method of treating acid-base disorders
GB2567616B (en) Treatment method
IL267229A (en) Methods of treating ocular disorders
EP3740201A4 (en) Method of treating acid-base disorders
EP3684342C0 (en) Method of treatment
GB201706406D0 (en) Method of treatment
HK1247818A1 (en) Method of treating diseases
GB201815588D0 (en) Method of treatment
IL272092A (en) Methods of treating behavior alterations
GB2571601B (en) Treatment method
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11202001806TA (en) Treatment method
IL270867A (en) Treatment method
GB201602802D0 (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
SG11202105877YA (en) Method of treatment
GB201500555D0 (en) Method and device for the treatment of diseases
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment